Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Immedica Pharma has announced its intention to acquire Marinus Pharmaceuticals for $0.55 per share, which implies an enterprise value of approximately $151 million. The acquisition comes shortly after Orion and Marinus terminated their agreement regarding the drug ganaxolone in Europe. Following the news of the acquisition, shares of Marinus Pharmaceuticals saw a pre-market increase of 43.2%. This strategic merger is expected to reshape the landscape for both companies involved.
$VINC (+57.9% pre) Vincerx Pharma Announces Merger, Leadership Changes, and Financing - TR https://t.co/obqbCKouEW
$MRNS (+43.2% pre) Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - BW https://t.co/pGmLZ3kiHt
Upside: $PLRZ +58% (announces publication of U.S. National Patent application for Its innovative hydrogel nasal technologies) $MRNS +43% (Orion and Marinus terminate agreement for ganaxolone in Europe; to be acquired by Immedica for $0.55/shr in cash) $MBOT +14% (concludes…
